Skip to content
← All ETFs
XBI

SPDR S&P Biotech ETF

Tracks the S&P Biotechnology Select Industry Index using an equal-weight methodology, tilting toward smaller biotech companies rather than mega-caps. Higher risk/reward profile than market-cap-weighted biotech funds. Sensitive to FDA approvals and clinical trial outcomes.

TER
0.35%
AUM
$8B
CAGR
11.3%
Volatility
27.0%
Max Drawdown
-56.7%
Data Range
2006-03 → 2026-04

Performance Analysis

Maximum Drawdown History

How far the ETF has fallen from its all-time high at each point. Deeper = more painful.

Current DD-10.2%
Worst DD-56.7%
Worst date2023-10

Rolling Returns

Annualized returns over rolling windows. Shows the range of outcomes depending on when you invested.

Avg return11.3%
Best44.4%
Worst-17.2%
% positive80%
206 periods

Key Facts

ISIN
US78464A8707
Issuer
State Street
Benchmark
S&P Biotechnology Select Industry Index
Total Expense Ratio (TER)
0.35%
Assets Under Management
$8B approx.
Inception Date
2006-01-31
Domicile
United States
Legal Structure
Open-Ended Fund
Dividend Policy
Distributing (pays dividends)
Replication Method
Physical (Full Replication)
UCITS Status
✗ Not UCITS
Fund Currency
USD
Primary Exchange
NYSE Arca
Number of Holdings
~150
Backtest this ETFOfficial Fund Page

Who Is This ETF For?

General portfolio building block for the asset class it covers.

Key Risks to Consider

Market risk: equity values can drop 30-50% in severe bear markets.

Non-UCITS: may have unfavorable tax treatment for non-US investors (US estate tax, withholding tax).

Similar ETFs

Related Tools

Data & Methodology

Metadata sourced from official issuer documentation. Price data from Yahoo Finance (monthly adjusted close, includes reinvested dividends and splits). AUM figures are approximate and updated quarterly.

Data source: Yahoo Finance (adjusted close), State Street (metadata)Last verified: 2026-04-16